Alnylam Pharmaceuticals has had a difficult run over the past year, with the share price down 46.8%, while the current valuation checks still lean toward the stock being on the expensive side rather than a clear bargain.

• Over the past 12 months, Alnylam Pharmaceuticals shareholders have seen the stock decline 46.8%, which puts a spotlight on whether earlier optimism was too strong.
• Upcoming clinical data on RNAi programs like the transthyretin and hypertension studies can support sentiment if they extend the commercial story, while any setback or slower than hoped progress in these programs may weigh on how much investors are willing to pay for future cash flows.
• Alnylam Pharmaceuticals scores 2 of 6 on the broader valuation checks, which suggests the stock currently leans expensive rather than offering clear value based on these metrics.

The issue now is whether the current price of Alnylam Pharmaceuticals still builds in assumptions that are too rich after such a large share price pullback.

Does Alnylam Pharmaceuticals Look Pricey on Earnings?

The P/E ratio is a simple way to see how much investors are paying for each dollar of Alnylam Pharmaceuticals earnings. For a company where earnings are an important benchmark, it can give a quick sense of how expectations compare with peers.

Alnylam Pharmaceuticals currently trades on a P/E of 40.8x, which is higher than the broader Biotechs industry average of 17.4x and also above the peer group average of 34.0x. A tailored fair P/E ratio for the company is estimated at 32.4x, based on its profile relative to similar stocks. This points to the current valuation sitting above what that framework suggests would be reasonable.

Despite anticipation around new RNAi data for transthyretin and hypertension programs at ESC Congress 2026, the P/E still implies investors are paying a premium compared with both sector averages and that fair ratio benchmark.

On the P/E multiple, Alnylam Pharmaceuticals stock appears overvalued compared with both its own fair ratio and the wider biotech peer group.

The Alnylam Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Alnylam Pharmaceuticals are designed to link the current P/E discussion with clear, evidence based stories about what Alnylam Pharmaceuticals' future growth, margins and earnings would need to look like for the stock to be worth materially more or materially less than today's price. Each Narrative anchors a fair value to a specific view of the company's possible catalysts and risks so you can track over time which version of events appears to be taking shape.

One of the top community narratives on Alnylam Pharmaceuticals: 46% undervalued

"Advancing pipeline assets and leadership in rare disease innovation position the company to benefit from ongoing healthcare sector trends and precision medicine expansion..."

Do you think there's more to the story for Alnylam Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For Alnylam Pharmaceuticals, the current valuation screens as overvalued on P/E and other broad checks, even after a difficult year for the stock. That does not rule out future upside, but it does mean expectations around its RNAi pipeline and commercial execution already carry a premium. The key question now is whether upcoming clinical milestones and eventual earnings delivery can grow into that multiple, or whether the market tempers what it is willing to pay for those potential cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.